JW Asset Management’s Alexion Pharmaceuticals ALXN Stock Holding History

JW Asset Management’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-25,424	Closed	-$3.54M	–	44
2016 Q1	$3.54M	Sell	25,424 -8,000	-24%	-$1.17M	2.31%	14
2015 Q4	$6.38M	Hold	33,424	–	–	2.38%	12
2015 Q3	$5.23M	Buy	33,424 +314	+0.9%	+$57.3K	1.89%	14
2015 Q2	$5.99M	Buy	33,110 +881	+3%	+$152K	1.82%	14
2015 Q1	$5.58M	Buy	32,229 +8,021	+33%	+$1.45M	2.42%	13
2014 Q4	$4.48M	Buy	+24,208	New	+$4.49M	3.36%	11

Other funds holding ALXN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

JW Asset Management's ALXN Position: Q2 2016 in Review

JW Asset Management sold out of Alexion Pharmaceuticals (ALXN) in Q2 2016, closing a stake of 25,424 shares — an estimated $3.54M sold.

JW Asset Management first reported a position in ALXN in Q4 2014 and held it in 6 quarters. The position peaked at $6.38M in Q4 2015. 533 funds tracked by Wall St. Rank hold ALXN as of Q2 2016.

JW Asset Management reported no remaining Alexion Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
JW Asset Management sold 25,424 Alexion Pharmaceuticals shares in Q2 2016, an estimated $3.54M.
JW Asset Management first reported a position in Alexion Pharmaceuticals in Q4 2014 and held it in 6 quarters.
JW Asset Management's Alexion Pharmaceuticals position peaked at $6.38M in Q4 2015.
533 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2016.

Based on JW Asset Management's 13F filing for Q2 2016, filed 12 Aug 2016.